Buprenorphine Other names: Buprenorphine hydrochloride

Chemical formula: C₂₉H₄₁NO₄  Molecular mass: 467.64 g/mol  PubChem compound: 644073

Therapeutic indications

Buprenorphine is indicated for:

Opioid dependence

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Severe pain

Population group: only adults (18 years old or older)

Buprenorphine is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Buprenorphine is contraindicated in the following cases:

Acute or severe bronchial asthma

Airway hyperreactivity

Acute alcoholism, delirium tremens

at least one of
Alcohol intoxication
Alcohol withdrawal delirium

Severe hepatic impairment

Hepatic failure stage IV

Severe respiratory insufficiency

Respiratory insufficiency

Hypersensitivity to buprenorphine

Buprenorphine allergy

Gastrointestinal obstruction, paralytic ileus

at least one of
Gastrointestinal obstruction
Paralytic ileus

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2019: BUTRANS Transdermal system
Summary of Product Characteristics (SPC) 2021: BUVIDAL Prolonged-release solution for injection
Structured Product Labeling (SPL/PLR) 2021: SUBLOCADE Solution for injection
Summary of Product Characteristics (SPC) 2020: SIXMO Implant
Summary of Product Characteristics (SPC) 2019: BUPRENORPHINE Sublingual tablet
Summary of Product Characteristics (SPC) 2021: RELETRANS Transdermal patch
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈